July 01, 2025 a 08:38 pm
JNJ: Analysts Ratings - Johnson & Johnson
Johnson & Johnson (JNJ) remains a key player in the healthcare industry, with diversified interests across pharmaceuticals, consumer health, and medical devices. Analysts' sentiment toward JNJ is relatively stable, with a tendency toward holding positions. The absence of Sell recommendations indicates a strong belief in the company's enduring market position, despite current market challenges.
Historical Stock Grades
Johnson & Johnson's latest analyst ratings show a dominance of Hold recommendations, accounting for nearly half of all opinions, reflecting a cautious market outlook while maintaining confidence in the company's resilience.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 7 | |
| Hold | 13 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, JNJ's analyst sentiment shows a stable pattern, with a predominant Hold perspective. Key highlights include:
- Stable Strong Buy recommendations at 4, indicating consistent confidence in JNJ's potential.
- A slight fluctuation in Buy ratings, indicating mixed reactions to short-term market changes.
- Hold ratings remain high, suggesting uncertainty about immediate growth but long-term stability.
- Lack of Sell or Strong Sell ratings reinforces JNJ's solid market position.
Percentage Trends
The distribution of analyst ratings for JNJ shows subtle trends towards a cautious approach:
- The proportion of Hold ratings has remained dominant, reflecting market stability amidst economic fluctuations.
- Buy ratings have slightly fluctuated, indicating cautious optimism among market analysts.
- No Sell recommendations were present, illustrating general confidence in the company’s steady performance.
Overall, the last year has shown minor shifts, with more restraint in Buy recommendations and consistent reliance on holds.
Latest Analyst Recommendations
Recent analyst actions reinforce a stable outlook for JNJ, with most recommendations being maintained:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-06-05 | Outperform | Outperform | RBC Capital |
| 2025-05-13 | Market Perform | Outperform | Leerink Partners |
| 2025-04-17 | Equal Weight | Equal Weight | Barclays |
| 2025-04-16 | Outperform | Outperform | Raymond James |
| 2025-04-16 | Equal Weight | Equal Weight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
Several changes in recommendations highlight varying market assumptions:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-13 | Market Perform | Outperform | Leerink Partners |
| 2025-04-09 | Buy | Neutral | Goldman Sachs |
| 2024-07-23 | Neutral | Outperform | Daiwa Capital |
| 2024-04-18 | Buy | Hold | HSBC |
| 2023-12-13 | Equal Weight | Overweight | Wells Fargo |
Interpretation
Analyst sentiment for Johnson & Johnson indicates a cautious yet confident outlook. The predominance of Hold ratings suggests uncertainty regarding short-term growth but confidence in long-term stability. The absence of Sell recommendations suggests little fear of downturns. The few downgrades hint at market jitters, yet strong buy ratings underscore confidence in JNJ's durability.
Conclusion
Johnson & Johnson's stock maintains a solid position within the healthcare market, marked by stable Hold and Buy ratings. The absence of negative sentiment bolsters confidence in its resilience, although cautious market behavior warrants watchful waiting. Recent shifts in analyst recommendations indicate minor market fluctuations rather than fundamental concerns, supporting a broadly positive long-term outlook.